In summary, integrated genetic and molecular profiles confirm genetic alterations of the EGFR signaling pathway, including amplification of the EGFR gene itself and the high expression of EGFR protein, as potential key targetable oncogenic events in MPNST. This evidence concerns the gene EGFR and malignant peripheral nerve sheath tumor.